11/28
08:14 pm
goss
How Recent Developments Are Shaping the Gossamer Bio Investment Story [Yahoo! Finance]
Medium
Report
How Recent Developments Are Shaping the Gossamer Bio Investment Story [Yahoo! Finance]
11/24
04:01 pm
goss
Gossamer Bio to Participate in Upcoming Investor Conferences
Low
Report
Gossamer Bio to Participate in Upcoming Investor Conferences
11/7
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/7
07:31 am
goss
Gossamer Bio to Participate in Upcoming Investor Conferences
Low
Report
Gossamer Bio to Participate in Upcoming Investor Conferences
11/5
05:37 pm
goss
Gossamer Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $13.29M beats by $6.91M [Seeking Alpha]
Medium
Report
Gossamer Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $13.29M beats by $6.91M [Seeking Alpha]
11/5
04:01 pm
goss
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
10/22
07:00 am
goss
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Neutral
Report
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
10/7
08:56 am
goss
How companies are steering IPO plans amid U.S. government shutdown [BNN Bloomberg (Canada)]
Medium
Report
How companies are steering IPO plans amid U.S. government shutdown [BNN Bloomberg (Canada)]
10/6
07:14 am
goss
Chiesi buys into Arbor gene editing drug for rare kidney disease [Yahoo! Finance]
Medium
Report
Chiesi buys into Arbor gene editing drug for rare kidney disease [Yahoo! Finance]
9/25
08:17 am
goss
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension [Yahoo! Finance]
Medium
Report
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension [Yahoo! Finance]
9/25
08:12 am
goss
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital [Yahoo! Finance]
Medium
Report
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital [Yahoo! Finance]
9/25
07:41 am
goss
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Medium
Report
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
9/25
07:31 am
goss
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension
Medium
Report
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension
9/22
08:04 am
goss
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 [Yahoo! Finance]
Medium
Report
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 [Yahoo! Finance]
9/22
07:31 am
goss
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
Medium
Report
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
9/21
03:21 am
goss
Medium
Report
9/15
07:14 am
goss
Gossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst Optimism [Yahoo! Finance]
Medium
Report
Gossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst Optimism [Yahoo! Finance]
9/13
09:25 am
goss
Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress [Yahoo! Finance]
Medium
Report
Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress [Yahoo! Finance]
9/11
08:42 am
goss
Gossamer Bio (NASDAQ:GOSS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
9/11
03:55 am
goss
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case [Yahoo! Finance]
Medium
Report
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case [Yahoo! Finance]
9/10
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/10
08:00 am
goss
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $9.00 price target on the stock, up previously from $1.25.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $9.00 price target on the stock, up previously from $1.25.